Arthritis Res Ther. 2011 Apr 27;13(2):111. doi: 10.1186/ar3308.
It has long been recognized that laboratory tests are useful in the diagnosis of disease and to monitor treatment outcome. Their performance has become even more demanding with the development of personalized medicine. In patients with rheumatoid arthritis (RA) the standard biochemical tests measure serological markers of disease, such as C-reactive protein, and RA-associated auto-antibodies, such as rheumatoid factor and anti-citrullinated protein antibodies. The information obtained from these markers does not, however, provide a complete picture of the disease and treatment efficacy. New biomarkers based on cytokine receptor complexes are promising for RA theragnostics.
长期以来，人们已经认识到实验室检测在疾病诊断和监测治疗结果方面非常有用。随着个性化医疗的发展，对它们的性能要求变得更高了。在类风湿关节炎（RA）患者中，标准的生化检测测量疾病的血清学标志物，如 C 反应蛋白，以及与 RA 相关的自身抗体，如类风湿因子和抗瓜氨酸化蛋白抗体。然而，这些标志物所提供的信息并不能完整地反映疾病和治疗效果。基于细胞因子受体复合物的新型生物标志物在 RA 治疗方面很有前景。
